Form 4: Sutro Biopharma CFO Edward Albini Reports Stock Transactions

CFO of Sutro Biopharma, Edward Albini, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Summary

• Edward Albini, CFO and Secretary of Sutro Biopharma, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2025, Albini vested 7,875 shares of common stock and 7,875 restricted stock units (RSUs) that vest annually beginning March 1, 2024.
• Additionally, 17,250 shares of common stock and 17,250 RSUs vested, with these RSUs vesting annually beginning March 1, 2025.
• 10,320 shares were withheld by the issuer to cover income tax obligations at a price of $1.59 per share.
• Following these transactions, Albini directly owns 121,548 shares of common stock and holds 15,750 RSUs that vest beginning March 1, 2024, and 51,750 RSUs that vest beginning March 1, 2025.

Sentiment

Score: 5

Explanation: This is a routine filing of stock transactions by a company executive, and does not contain information that would significantly impact investor sentiment.

Future Outlook

The RSUs will continue to vest annually, subject to continued service.

Industry Context

Form 4 filings are standard practice for company insiders to report their transactions in company stock, providing transparency to investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Vesting schedules, like the annual vesting described in the document, are common in the industry to incentivize long-term commitment.
• Companies like Amgen, Gilead, and Biogen also use RSUs as part of their executive compensation packages.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• Employees holding RSUs are impacted as their awards vest over time, subject to continued service.

Key Dates